文献速递心境障碍焦虑、强迫与应激相关障碍

他汀类药物使用与自杀、抑郁、焦虑及癫痫发作的关联:瑞典全人群队列研究

Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study.
PubMed 文献 · Lancet Psychiatry · 2020-01-01

该研究基于瑞典全国登记数据,纳入2006—2013年间配发他汀且年龄≥15岁的1 149 384人,采用个体内分层Cox回归比较用药期与非用药期结局。结果显示他汀使用与自杀行为或自杀死亡、焦虑障碍、癫痫发作无明确关联,与抑郁障碍风险降低相关,但该关联可能受非特异性用药获益混杂,仍需进一步研究。

要点

  • 他汀使用与自杀行为或自杀死亡、焦虑障碍及癫痫发作无明确关联。
  • 他汀使用与抑郁障碍风险降低相关,调整抗抑郁药使用后仍存在,但可能受非特异性混杂影响。

核心结论

  • 他汀使用与自杀倾向、焦虑障碍或癫痫发作无关,与临床抑郁诊断减少的关联是否受非特异性获益混杂尚需进一步研究。

研究设计与样本

  • 采用个体内设计,以分层Cox比例风险回归比较同一个体他汀用药期与非用药期结局发生率,从而调整不随时间变化的混杂因素。
  • 通过同一队列中噻嗪类利尿剂和抗组胺药使用与上述结局的关系检验治疗的非特异性效应。

主要发现

  • 他汀使用者队列共1 149 384人,其中1 015 949人(88·4%)年龄≥50岁,625 616人(54·4%)为男性,523 768人(45·6%)为女性。
  • 研究期间共2 053 310个非治疗期和2 997 545个治疗期,957 216人(83·3%)发生用药状态改变。
  • 自杀结局见于6372人(0·6%),抑郁障碍23 745人(2·1%),焦虑障碍30 100人(2·6%),癫痫发作28 844人(2·5%)。
  • 他汀治疗期与自杀行为或自杀死亡(HR 0·99[95%CI 0·90-1·08])、焦虑障碍(0·99[0·95-1·02])、癫痫发作(1·00[0·97-1·04])无明确关联。
  • 他汀与抑郁障碍风险降低相关(0·91[0·87-0·94]),调整同期抗抑郁药使用后仍为0·91(0·88-0·94)。

关键数值与推荐

  • 抑郁障碍风险比:他汀使用0·91(95%CI 0·87-0·94);调整同期抗抑郁药使用后0·91(0·88-0·94)。
  • 抑郁障碍风险比:噻嗪类利尿剂使用0·61(0·38-1·00;n=14 718),抗组胺药使用0·84(0·67-1·06;n=23 715)。
  • 自杀行为或自杀死亡风险比0·99(95%CI 0·90-1·08),焦虑障碍0·99(0·95-1·02),癫痫发作1·00(0·97-1·04)。

临床怎么用

  • 对于使用他汀的患者,现有证据不支持其增加自杀、焦虑或癫痫发作风险。
  • 他汀与抑郁障碍诊断减少的关联可能反映非特异性用药获益,不宜据此直接将他汀用于抑郁治疗。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins have shown both protective and adverse associations with neuropsychiatric outcomes. We aimed to examine the possible associations between statins and suicidality, depression, anxiety, and seizures. METHODS: Using Swedish national registers, we linked data on dispensed statin prescriptions with data on unplanned (emergency) hospital visits or specialised outpatient care for four neuropsychiatric outcomes: suicidal behaviour (including deaths from suicide), depressive disorders, anxiety disorders, and seizures. We included all individuals in the registries who were dispensed statins and who were aged 15 years or older between Jan 1, 2006, and Dec 31, 2013. We applied a within-individual design using stratified Cox proportional hazards regression to compare the incidence of the defined outcomes during periods on statins and periods off statins within each individual, thus adjusting for time-invariant confounders. Non-specific effects of treatment were tested by investigating these outcomes in relation to thiazide diuretic use and antihistamine use in the same cohort. FINDINGS: The statin-users cohort comprised 1 149 384 individuals, of whom 1 015 949 (88·4%) were aged 50 years or older, 625 616 (54·4%) were male, and 523 768 (45·6%) were female. The study period consisted of 2 053 310 non-treatment periods and 2 997 545 treatment periods, and 957 216 (83·3%) individuals had a medication status change (from on statins to off statins, or vice versa). Suicide outcomes were found in 6372 (0·6%) individuals, depressive disorders in 23 745 (2·1%), anxiety disorders in 30 100 (2·6%), and seizures in 28 844 (2·5%). There were no clear associations between periods of statin treatment and suicidal behaviour or deaths from suicide (hazard ratio 0·99 [95% CI 0·90-1·08]), anxiety disorders (0·99 [0·95-1·02]), or seizures (1·00 [0·97-1·04]). Statins were associated with reduced hazards of depressive disorders (0·91 [0·87-0·94]), which remained after adjustment for concurrent antidepressant use (0·91 [0·88-0·94]). Hazard ratios for depressive disorders were 0·61 (0·38-1·00; n=14 718) with thiazide diuretic use and 0·84 (0·67-1·06; n=23 715) with antihistamine use. INTERPRETATION: Statin use is not associated with suicidality, anxiety disorders, or seizures. Whether the observed association between statin use and reduced diagnoses of clinical depression is confounded by non-specific benefits related to being prescribed medication needs further research. FUNDING: Wellcome Trust, Swedish Research Council, National Institute for Health Research (NIHR) Research Professorship, NIHR Oxford Health Biomedical Research Centre, American Foundation for Suicide Prevention, Karolinska Institutet.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Molero Y, Cipriani A, Larsson H, et al. Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study. Lancet Psychiatry. 2020. PMID: 33069320. doi:10.1016/S2215-0366(20)30311-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。